Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Fiche publication
Date publication
septembre 2019
Journal
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROUX Stéphane
Tous les auteurs :
Dufort S, Appelboom G, Verry C, Barbier EL, Lux F, Bräuer-Krisch E, Sancey L, Chang SD, Zhang M, Roux S, Tillement O, Le Duc G
Lien Pubmed
Résumé
We formulated an ultra-small, gadolinium-based nanoparticle (AGuIX) with theranostic properties to simultaneously enhance MRI tumor delineation and radiosensitization in a glioma model. The 9L glioma cells were orthotopically implanted in 10-week-old Fischer rats. The intra-tumoral accumulation of AGuIX was quantified using MRI T1-maps. Rats randomized to intervention cohorts were subsequently treated with daily temozolomide for five consecutive days before radiotherapy treatment. Collectively, a series of 32 rats were divided into untreated (n = 7), temozolomide-only (n = 7), temozolomide and MRT (n = 9), AGuIX and MRT (n = 7), and triple therapy (temozolomide, AGuIX NPs, and MRT; n = 9) cohorts. AGuIX nanoparticles achieved a maximum intra-tumoral concentration (expressed as concentration of Gd3+) at 1 h after intravenous injection, reaching a mean of 227.9 ± 60 μM. This was compared to concentrations of 10.5 ± 9.2 μM and 62.9 ± 24.7 μM in the contralateral hemisphere and cheek, respectively. There was a slower washout in the intra-tumor region, with sustained tumor-to-contralateral ratio of AGuIX, up to 14-fold, for each time point. The combination of AGuIX or temozolomide with MRT improved the median survival time (40 days) compared to the MeST of control rats (25 days) (p < 0.002). There was a trend towards further increased survival when the three treatments were combined (MeST of 46 days). This study demonstrated the selective accumulation of AGuIX in high grade glioma, as well as the potential survival benefits when combined with chemoradiation.
Mots clés
Chemoradiation, Glioblastoma, Nanoparticles, Radiosensitizers, Temozolomide, Theranostic
Référence
J Clin Neurosci. 2019 Sep;67:215-219